McGill Placebo Brain Cells Study | Neuroscience Breakthrough
McGill University researchers identify specific brain cells driving the placebo effect, revolutionizing pain treatment and clinical trials in Canada.
No reviews yet. Be the first to rate Gustavo!
Dr. Gustavo Turecki is a Professor and the Chair of the Department of Psychiatry at McGill University. He serves as Director of the McGill Group for Suicide Studies, a multidisciplinary research group focused on suicide research involving psychology, epidemiology, anatomy, and molecular biology. He is also the Scientific Director of the Douglas Research Centre and the Psychiatrist-in-Chief of the Douglas Mental Health University Institute, where he heads the Depressive Disorders Program for patients with refractory major depressive disorder.
Dr. Turecki holds an MD and a PhD. As a clinician-scientist, his work centers on the neurobiology of depression and suicide, with emphasis on functional genomics and epigenetics. He examines the role of epigenetic risk factors in major depression and suicidal behaviour through integrated clinical and basic research approaches. His expertise encompasses suicide, depressive disorders, and treatment-resistant major depressive disorder. Dr. Turecki holds a Tier 1 Canada Research Chair in Major Depressive Disorder and Suicide. He has authored numerous publications in leading journals and contributes to advancing understanding of molecular mechanisms underlying these conditions.
McGill University researchers identify specific brain cells driving the placebo effect, revolutionizing pain treatment and clinical trials in Canada.
Explore McGill University's groundbreaking discovery identifying specific brain cells altered in depression, paving the way for targeted therapies and advancing higher education neuroscience research.
McGill University's study in Nature Genetics reveals specific excitatory neurons and microglia changes in depression, advancing targeted treatments and highlighting Canada's research leadership.